Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
Gene expression in primary non-small cell lung cancer as a predictor of brain metastases

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 396
Rating:

Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel

Dr Jair Bar speaks to ecancer at the WIN 2019 Symposium in Paris about the use of gene expression in primary non-small cell lung cancer (NSCLC) to identify patients at risk of developing brain metastases.

He mentions how these lung cancer patients may be prone to developing brain metastases and how these underlying mechanisms are poorly understood.

By comparing resected tumours after surgery between patients with and without brain metastases, it was possible to identify a set of predictive genes for brain metastases rather than relying solely on clinical data.

In terms of underlying mechanisms, Dr Bar states that oxidative phosphorylation was found to be increased in patients with brain metastases.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation